Brief: Ultimovacs Sees Topline Results From UV1 Phase II Trial INITIUM In March

Zelluna ASA

16/01/2024 06:06

Jan 16 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * UPDATES TIMELINE FOR REPORTING ON RANDOMIZED UV1 PHASE II TRIAL INITIUM IN MALIGNANT
MELANOMA;
TOPLINE RESULTS EXPECTED IN MARCH 2024

Source text for Eikon:  ID: 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))